Actively Recruiting
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
Led by Mayo Clinic · Updated on 2026-04-09
70
Participants Needed
2
Research Sites
250 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers. Increasing CLL patients overall physical fitness levels, through exercise during the observation stage, may provide a realistic approach means to increase survival, decrease treatment-related side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be used to strengthen the immune system of indolent NHL and CLL patients, delay time to disease progression, assess the need for treatment, and assess infection rates.
CONDITIONS
Official Title
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- English speaking
- Between the ages of 18-80
- Histologically confirmed diagnosis of indolent non-Hodgkin lymphoma (NHL) is required for participation in Aims 2, 3, 4, and 5
You will not qualify if you...
- Healthy participants in Aim 1 with known cardiovascular or pulmonary disease (e.g., heart disease, coronary artery disease, COPD, asthma) are excluded
- Participants with orthopedic or musculoskeletal limitations affecting exercise ability are excluded
- Current or former smokers are excluded from Aim 1
- Indolent NHL patients receiving treatment must have at least 8 weeks of planned treatment remaining
- Patients who have completed treatment must be at least 6 months post-treatment with no planned treatments during the 12-week intervention
- Participants prior to treatment must have no scheduled treatments during participation
- Individuals with uncontrolled hypertension or cardiac illness are excluded
- Participation requires oncologist approval
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
Actively Recruiting
2
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
C
Courtney Wheatley-Guy, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here